Typcal, a Brazilian producer of sustainable mycoprotein ingredients, has announced the inauguration of a new production facility in the municipality of Pinhais, part of the Metropolitan region of the city of Curitiba.
The facility will allow Typcal to commence commercial-scale production, which could enable the company to begin selling its ingredients in Europe and Latin America by next year. Typcal will initially offer fresh and powdered mycoprotein products, but is also reportedly developing two more solutions that could be available by the end of 2026.
The facility has been designed for future expansion and is claimed to be South America’s first large-scale fermentation plant dedicated to the production of mycoproteins.
“Having our own plant is a game-changer,” said Paulo Ibri, CEO and co-founder of Typcal. “This places us among the very few startups in the world that manage to advance from pilot to industrial scale, especially in a segment as challenging as new proteins. It’s a pioneering, innovative, and bold step — three pillars that have always guided Typcal.”
Building a more positive food system
The development has been made possible by a R$10 million ($1.81 million) investment from Brazilian investors and the biotech incubator program Biotope. Typcal was accepted into the seventh cohort of the incubator in September; participants receive €250,000 in direct funding and €100,000 in non-cash tailored support.
The company previously secured R$250,000 (around $45,000) from the Brazilian government in 2024.
“We are the only company in the world building a portfolio of mycelium-based ingredients,” said Typcal CTO and co-founder Eduardo Sydney. “We already have two mycelium ingredients ready for the market and two more in the pipeline. This reinforces not only our technological capabilities, but also our vision for the future and our responsibility to build a more positive food system for people and the planet.”
